247 related articles for article (PubMed ID: 18501085)
21. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
Hong RL; Tseng YL
Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101).
Gaillard PJ; Appeldoorn CC; Dorland R; van Kregten J; Manca F; Vugts DJ; Windhorst B; van Dongen GA; de Vries HE; Maussang D; van Tellingen O
PLoS One; 2014; 9(1):e82331. PubMed ID: 24416140
[TBL] [Abstract][Full Text] [Related]
23. Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity.
Ho KW; Chen IU; Cheng YA; Liao TY; Liu ES; Chen HJ; Lu YC; Su YC; Roffler SR; Huang BC; Liu HJ; Huang MY; Chen CY; Cheng TL
J Nanobiotechnology; 2021 Jan; 19(1):16. PubMed ID: 33422061
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic efficacy of combining pegylated liposomal doxorubicin and radiofrequency (RF) ablation: comparison between slow-drug-releasing, non-thermosensitive and fast-drug-releasing, thermosensitive nano-liposomes.
Andriyanov AV; Koren E; Barenholz Y; Goldberg SN
PLoS One; 2014; 9(5):e92555. PubMed ID: 24786533
[TBL] [Abstract][Full Text] [Related]
25. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients.
La-Beck NM; Zamboni BA; Gabizon A; Schmeeda H; Amantea M; Gehrig PA; Zamboni WC
Cancer Chemother Pharmacol; 2012 Jan; 69(1):43-50. PubMed ID: 21590446
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer.
Mayer C; Brucker J; Schuetz F; Domschke C; Bechstein S; Heil J; Golatta M; Wallwiener M; Sohn C; Schneeweiss A; Rom J
Arch Gynecol Obstet; 2016 Jul; 294(1):123-9. PubMed ID: 26498757
[TBL] [Abstract][Full Text] [Related]
27. A pegylated liposomal platform: pharmacokinetics, pharmacodynamics, and toxicity in mice using doxorubicin as a model drug.
Lu WL; Qi XR; Zhang Q; Li RY; Wang GL; Zhang RJ; Wei SL
J Pharmacol Sci; 2004 Jul; 95(3):381-9. PubMed ID: 15272215
[TBL] [Abstract][Full Text] [Related]
28. Pegylated Liposomal Doxorubicin as Adjuvant Therapy for Stage I-III Operable Breast Cancer.
Lu YC; Ou-Yang FU; Hsieh CM; Chang KJ; Chen DR; Tu CW; Wang HC; Hou MF
In Vivo; 2016; 30(2):159-63. PubMed ID: 26912829
[TBL] [Abstract][Full Text] [Related]
29. Short-time focused ultrasound hyperthermia enhances liposomal doxorubicin delivery and antitumor efficacy for brain metastasis of breast cancer.
Wu SK; Chiang CF; Hsu YH; Lin TH; Liou HC; Fu WM; Lin WL
Int J Nanomedicine; 2014; 9():4485-94. PubMed ID: 25278753
[TBL] [Abstract][Full Text] [Related]
30. Study of FA12 peptide-modified PEGylated liposomal doxorubicin (PLD) as an effective ligand to target Muc1 in mice bearing C26 colon carcinoma: in silico, in vitro, and in vivo study.
Biabangard A; Asoodeh A; Jaafari MR; Mashreghi M
Expert Opin Drug Deliv; 2022 Dec; 19(12):1710-1724. PubMed ID: 36373415
[TBL] [Abstract][Full Text] [Related]
31. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR
Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343
[TBL] [Abstract][Full Text] [Related]
32. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.
Tuscano JM; Martin SM; Ma Y; Zamboni W; O'Donnell RT
Clin Cancer Res; 2010 May; 16(10):2760-8. PubMed ID: 20460479
[TBL] [Abstract][Full Text] [Related]
33. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma.
Cooley T; Henry D; Tonda M; Sun S; O'Connell M; Rackoff W
Oncologist; 2007 Jan; 12(1):114-23. PubMed ID: 17227906
[TBL] [Abstract][Full Text] [Related]
34. Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?
Theodoulou M; Hudis C
Cancer; 2004 May; 100(10):2052-63. PubMed ID: 15139046
[TBL] [Abstract][Full Text] [Related]
35. Skin-mucous membrane disorder and therapeutic effect of pegylated liposomal doxorubicin in recurrent ovarian cancer.
Yamada Y; Kawaguchi R; Ito F; Iwai K; Niiro E; Shigetomi H; Tanase Y; Kobayashi H
J Obstet Gynaecol Res; 2017 Jul; 43(7):1194-1199. PubMed ID: 28544386
[TBL] [Abstract][Full Text] [Related]
36. Safety aspects of pegylated liposomal doxorubicin in patients with cancer.
Alberts DS; Garcia DJ
Drugs; 1997; 54 Suppl 4():30-5. PubMed ID: 9361959
[TBL] [Abstract][Full Text] [Related]
37. Optimizing Antitumor Efficacy and Adverse Effects of Pegylated Liposomal Doxorubicin by Scheduled Plasmapheresis: Impact of Timing and Dosing.
Ngoune R; Contini C; Hoffmann MM; von Elverfeldt D; Winkler K; Putz G
Curr Drug Deliv; 2018; 15(9):1261-1270. PubMed ID: 29779479
[TBL] [Abstract][Full Text] [Related]
38. Monitoring long-term treatment with pegylated liposomal doxorubicin: how important is intensive cardiac follow-up?
Grenader T; Goldberg A; Gabizon A
Anticancer Drugs; 2010 Oct; 21(9):868-71. PubMed ID: 20679886
[TBL] [Abstract][Full Text] [Related]
39. Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines.
Verma S; Dent S; Chow BJ; Rayson D; Safra T
Cancer Treat Rev; 2008 Aug; 34(5):391-406. PubMed ID: 18358614
[TBL] [Abstract][Full Text] [Related]
40. Preclinical studies of pegylated- and non-pegylated liposomal forms of doxorubicin as radiosensitizer on orthotopic high-grade glioma xenografts.
Chastagner P; Sudour H; Mriouah J; Barberi-Heyob M; Bernier-Chastagner V; Pinel S
Pharm Res; 2015 Jan; 32(1):158-66. PubMed ID: 25048636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
